LEO Pharma
LEO Pharma
Revenue(RF), mln.USD
29
Assets(RF), mln.USD
28
Capital(RF), mln.USD
26
Staff(RF), 2021
100
Taxes(RF), mln.USD
3
The Company Statement
July 22, 2026
Leo Pharma’s Russian subsidiary, LLC Leo Pharma Products, has earned at least DKK 113m (USD 17.2m) from the sale of eczema creams and ointments since the invasion of Ukraine. In addition, the company has built up equity of over a quarter of a billion Danish kroner.
| July 22, 2026 | While Russia continues its war in Ukraine, LEO Pharma is earning significant sums by selling the company’s products on the Russian market. |
All company names used on this web page are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
Company statements and statistical data are collected from open sources and official registers according to the methodology of the KSE Institute.
Scanner